[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.207.116. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 19, 2002

α-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(23):3080-3081. doi:10.1001/jama.287.23.3077

To the Editor: Dr Rubin and colleagues suggested that α-methylacyl coenzyme A racemase (AMACR) may be a tissue biomarker for prostate cancer.1 We agree that AMACR is a promising diagnostic marker for prostate cancer and recently reported that AMACR has high sensitivity for the detection of prostate cancer on needle biopsy.2 However, it is important to recognize the limitations of this marker. In our study of atypical adenomatous hyperplasia of the prostate, a benign condition that mimics prostate cancer, AMACR immunoreactivity was found in a small subset of cases (17.5%).3 Therefore, caution should be exercised in interpretation of AMACR immunostaining.

First Page Preview View Large
First page PDF preview
First page PDF preview
×